Floatz logo

1H-ISOINDOL-1-ONE, 7-((6-((DIMETHYLAMINO)METHYL)-5-((3S)-TETRAHYDRO-3-FURANYL)-2-PYRIDINYL)AMINO)-4-(7-FLUOROIMIDAZO(1,2-A)PYRIDIN-3-YL)-2,3-DIHYDRO-

Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Nimbus Saturn, Inc.Small moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

40 Active assets in the Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Eloxatin
Memorial Sloan Kettering Cancer Center
Phase 3BB
Pembrolizumab
Diwakar Davar
Phase 3BB
Nivolumab
Memorial Sloan Kettering Cancer Center
Phase 2BB
TRASTUZUMAB
UNICANCER
Phase 3BB
LENVATINIB
Merck Sharp & Dohme LLC
Phase 3B

View all 50 →

Same molecule, other indications

1H-ISOINDOL-1-ONE, 7-((6-((DIMETHYLAMINO)METHYL)-5-((3S)-TETRAHYDRO-3-FURANYL)-2-PYRIDINYL)AMINO)-4-(7-FLUOROIMIDAZO(1,2-A)PYRIDIN-3-YL)-2,3-DIHYDRO- is also rated in:

renal cell carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
neoplasmDormant
CC
Indicative ·
40 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →